These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23323327)

  • 41. [Study of anticoagulant activity of ethanol extracts from leech in vitro].
    Feng GJ; Zhu ZG; Yu CL; Zhang Q; Chen NN; Lei LS; Wu SG
    Zhong Yao Cai; 2007 Aug; 30(8):909-11. PubMed ID: 18074833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
    Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
    Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
    Koestenberger M; Cvirn G; Gallistl S; Kutschera J; Muntean W
    Acta Paediatr; 2005 Jul; 94(7):884-9. PubMed ID: 16188810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anticoagulant effect of unfractionated heparin in antithrombin-depleted plasma in vitro.
    Krulder JW; Strebus AF; Meinders AE; Briët E
    Haemostasis; 1996; 26(2):85-9. PubMed ID: 9119287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults.
    Ignjatovic V; Summerhayes R; Yip YY; Monagle P
    Thromb Res; 2008; 122(5):709-14. PubMed ID: 18384841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
    Kher A; Gouin I; Samama MM
    Ann Biol Clin (Paris); 2000; 58(5):575-9. PubMed ID: 11022100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparative study of recombinant hirudin and standard heparin in the Wessler model.
    Bara L; Bloch MF; Samama MM
    Thromb Res; 1992 Oct; 68(2):167-74. PubMed ID: 1475779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray].
    Zhang YJ; Zhang Q; Hou JL; Wang XL; Chen MX
    Yao Xue Xue Bao; 2006 Mar; 41(3):268-71. PubMed ID: 16759001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics of a new DNA aptamer, direct inhibitor of thrombin.
    Mazurov AV; Titaeva EV; Khaspekova SG; Storojilova AN; Spiridonova VA; Kopylov AM; Dobrovolsky AB
    Bull Exp Biol Med; 2011 Feb; 150(4):422-5. PubMed ID: 22268033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNA aptamers for human thrombin with high anticoagulant activity demonstrate target- and species-specificity.
    Zavyalova E; Golovin A; Timoshenko T; Babiy A; Pavlova G; Kopylov A
    Curr Med Chem; 2012; 19(30):5232-7. PubMed ID: 22934762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Chitosan Derivative N-[(2-Hydroxy-3-Trimethylammonium)Propyl]Chloride on Anticoagulant Activity of Guinea Pig Plasma.
    Drozd NN; Shagdarova BT; Il'ina AV; Varlamov VP
    Bull Exp Biol Med; 2017 Jul; 163(3):340-343. PubMed ID: 28744652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model.
    Solis MM; Cook C; Cook J; Glaser C; Light D; Morser J; Yu SC; Fink L; Eidt JF
    J Vasc Surg; 1991 Nov; 14(5):599-604. PubMed ID: 1658403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase.
    Müller J; Freitag D; Mayer G; Pötzsch B
    J Thromb Haemost; 2008 Dec; 6(12):2105-12. PubMed ID: 18826387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
    Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
    Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.